Home Biosimilar Antibodies Angiogenesis VEGFR inhibitor Bevacizumab (anti-VEGF)
For research use only. Not for use in humans.

Bevacizumab (anti-VEGF)

Synonyms: rhuMab VEGF

Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.

Bevacizumab (anti-VEGF)

Click to purchase the isotype control of Bevacizumab (anti-VEGF)

48 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 98.95% Protein concentration: 4.94mg/ml Endotoxin Level: ≤1 EU/mg
98.95

Specificity

Name Citation VEGFR1 VEGFR2 VEGFR3 VEGFR VEGF Others
Foretinib 94 Met,Tie-2,RON
Cediranib (AZD2171) 67 c-Kit,PDGFRβ,FGFR1
PD173074 124 FGFR1
Dovitinib (TKI-258) 52 FLT3,c-Kit,FGFR1
Linifanib (ABT-869) 33 CSF-1R,FLT3,Kit
Vatalanib (PTK787) 2HCl 53 PDGFRβ,c-Kit,c-Fms
RAF265 (CHIR-265) 24 B-Raf
Motesanib Diphosphate (AMG-706) 12 Kit,RET,PDGFR
Brivanib (BMS-540215) 10 FGFR1
MGCD-265 analog 12 Met,RON,Tie-2
AEE788 (NVP-AEE788) 13 EGFR,HER2/ErbB2,c-Abl
ENMD-2076 9 FLT3,RET,Aurora A
OSI-930 7 CSF-1R,LCK,C-Raf
CYC116 10 Aurora A,Aurora B,FLT3
Ki8751 21 c-Kit,PDGFRα
Telatinib 5 c-Kit,PDGFRα
PP121 5 PDGFR,Hck,mTOR
KRN 633 6 PDGFRα,c-Kit,BTK
SAR131675 34
Apatinib (YN968D1) mesylate 26 RET
BMS-794833 2 Met
Brivanib Alaninate (BMS-582664) 2 FGFR1
Golvatinib (E7050) 8 c-Met
Semaxanib (SU5416) 21
ZM 323881 HCl 20
ZM 306416 13 Src,Abl
R1530 0 FGFR1
Chiauranib 0 c-Kit,CSF-1R,Aurora B
Emvododstat (PTC299) 0 Dihydroorotate dehydrogenase
XL092 0 AXL,MER,MET
Lucitanib (E3810) hydrochloride 1 FGFR1,FGFR2
Ningetinib 0 Axl,c-Met
Ki20227 1 c-Fms,PDGFRβ,c-Kit
Tyrphostin AG1433 0 PDGFRβ
SU14813 2 PDGFRβ,KIT
Sulfatinib 1 CSF1R,FGFR1
CS-2660 (JNJ-38158471) 0 RET,Kit
SU5204 1 HER2
SU5214 0 EGFR
SU5205 0
SU5408 2
Pamufetinib (TAS-115) 0 recombinant MET
ODM-203 0 FGFR3,FGFR1,FGFR2
WHI-P180 0 RET
Altiratinib 3 MET Y1230C,TrkA,TrkC
Motesanib (AMG-706) 11 c-Kit,c-Ret,PDGFR
Fruquintinib (HMPL-013) 6
Apatinib 28 RET
Cediranib Maleate 14 c-Kit,PDGFRβ,FGFR1
Toceranib phosphate 1 PDGFR
Anlotinib (AL3818) dihydrochloride 48 c-Kit
Sitravatinib (MGCD516) 7 DDR2,EPHA3,Axl
BFH772 0
BAW2881 (NVP-BAW2881) 3 C-Raf-1,B-RAFV599E,c-Abl
SU5402 24 FGFR1,PDGFRβ
Dovitinib (TKI258) Lactate monohydrate 31 FLT3,c-Kit,FGFR1
LY2874455 15 FGFR2,FGFR1,FGFR4
SKLB1002 5
AZD2932 3 PDGFRβ,Flt3,c-Kit
WAY-340935 0
hVEGF-IN-1 0
4SC-203 0
Chebulinic acid 0
Nastorazepide 0
Vorolanib 0 PDGFR
MAZ51 1 RhoA,GSK3β,Akt
SU5208 0
SU5614 3 FLT3,c-Kit,RET
AG-13958 0
SKLB 610 2 FGFR2,PDGFR
SU1498 2
ZD-4190 0 Flt-1
PDGFR inhibitor 1 4 PDGFR,Kit,c-Fms
Taxifolin (Dihydroquercetin) 4
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.
Features
Human IgG1
Targets/IC50/Ki
VEGFR2
VEGF-A
VEGF
In vitro

Blocking VEGF with bevacizumab reduces the proangiogenic effect of affected fibroblasts in both the matrigel and direct coculture angiogenesis models.
Cell Research

Matrigel gels were created using low GF Matrigel (protein concentration > 9.5 mg/ml) in a 48-well plate. It was gelled at 37 ℃ overnight and then rinsed twice with PBS. endothelial cells (ECs) were added in 250 μl endothelial basal medium with no supplement and allowed to adhere for 1 hour. An additional 250 μl of 48 h conditioned medium from unaffected or affected fibroblasts or nonconditioned medium with or without 20 ng/ml VEGF and with or without 250 μl/ml bevacizumab in 5% FBS + 1% penicillin/streptomycin in DMEM was added, and ECs were incubated for 14 h before being fixed and stained for CD31. ECs network formation was also tracked by live-cell imaging at 2, 4, 8, 16, and 24 h.
In vivo

The combinational treatment of AAV9-LECT2-shRNA and bevacizumab significantly improves the therapeutic effects on liver fibrosis.
Animal Research

Animal Models: Male C57BL/6J mice of CCl4-induced fibrosis model
Dosages: 2 mg/kg
Administration: i.p.
Reference: https://pubmed.ncbi.nlm.nih.gov/34940991/
 
References

Product Details

CAS No. 216974-75-3
Isotype Human IgG1
Source CHO cells
Sterility 0.2 μM filtered
Formulation PBS buffer, pH 7.2
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.